Clinical Trials on Cystadenocarcinoma, Mucinous

Total 746 results

Lawson Health Research Institute
University of Western Ontario, Canada

Terminated

Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm

Mucinous Cystic Tumor With Moderate Dysplasia | Mucinous Cystadenoma of Pancreas | Mucinous Cystadenocarcinoma of Pancreas | Benign Neoplasm of Pancreas

Canada
University Hospital, Montpellier

Unknown

Non Ivasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis

Noninvasive Mucinous Cystadenocarcinoma of Ovary

France
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Stage III Ovarian Cancer

United States
Zhejiang Cancer Hospital

Unknown

A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)

Colorectal Cancer

China
University of Washington
National Cancer Institute (NCI)

Completed

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
Mucpharm Pty Ltd
Wake Forest University Health Sciences; Catharina Ziekenhuis Eindhoven; Hospital... and other collaborators

Not yet recruiting

BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei

Pseudomyxoma Peritonei | Peritoneal Cancer | Mucinous Adenocarcinoma | Mucinous Tumor
National Cancer Institute (NCI)

Completed

Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Mixed Epithelial Carcinoma | Ovarian Undifferentiated...

United States
National Cancer Institute (NCI)

Completed

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Undifferentiated Adenocarcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian... and other conditions

United States
University Hospital, Akershus
Oslo University Hospital; St. Olavs Hospital

Recruiting

METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin (METIMMOX-2)

Colorectal Adenocarcinoma | Mucinous Adenocarcinoma | Signet Ring Cell Adenocarcinoma

Norway
Northwell Health

Withdrawn

Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation

Uterine Carcinoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous... and other conditions

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Primary Peritoneal Cavity Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Ovarian Mucinous Cystadenocarcinoma | Ovarian Mixed Epithelial Carcinoma | Ovarian...

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States, Japan
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Fallopian Tube Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Brenner Tumor | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Gastrointestinal Complication and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Pain | Fatigue | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Neuropathy | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner... and other conditions
AstraZeneca
Parexel

Completed

A Study of Adavosertib as Treatment for Uterine Serous Carcinoma (ADAGIO)

Uterine Serous Carcinoma

United States, Italy, Spain, France, Canada
K-Group, Beta, Inc., a wholly owned subsidiary...

Recruiting

A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Uterine Serous Carcinoma

United States, Australia, Canada, Georgia
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Undifferentiated Carcinoma | Ovarian... and other conditions

United States, Canada, Singapore
Stony Brook University
University of Iowa; Ipsen; Barbara Ann Karmanos Cancer Institute

Completed

Phase I Trial HIPEC With Nal-irinotecan

Gastric Cancer | Colorectal Cancer | Mesothelioma | Pseudomyxoma Peritonei | Peritoneal Cancer | Mucinous Adenocarcinoma | Primary Peritoneal Carcinoma | Mucinous Tumor

United States
Yale University
Boehringer Ingelheim

Recruiting

A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma (Afatinib)

HER2/Neu+ Uterine Serous Carcinoma

United States
Abramson Cancer Center of the University of Pennsylvania

Terminated

Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

Mucinous Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon

United States
National Cancer Institute (NCI)

Recruiting

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

Endometrial Serous Adenocarcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer

Unresectable Malignant Solid Neoplasm | Endometrial Serous Adenocarcinoma | Metastatic Malignant Solid Neoplasm

United States
ZielBio, Inc.

Completed

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

Ovarian Serous Cystadenocarcinoma | Solid Tumor, Adult | Ovarian Serous Adenocarcinoma | Biliary Cancer Metastatic | Pancreatic Ductal; Adenocarcinoma

United States
Lei Li

Unknown

Immune Repertoire of Ovarian HGSC

Ovarian High Grade Serous Carcinoma | Immune Repertoire | T Lymphocyte Receptor | B Lymphocyte Receptor

China
Port Said University hospital
Mansoura University Hospital

Completed

PDL1 in Ovarian High Grade Serous Carcinoma

Ovarian Cancer

Egypt
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States
Casey Cosgrove

Recruiting

Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Recurrent Endometrial Serous Adenocarcinoma

United States
Port Said University hospital

Completed

Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.

Ovarian Cancer
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States
Gynecologic Oncology Group
Novartis

Active, not recruiting

Ribociclib and Letrozole Treatment in Ovarian Cancer

Low Grade Serous Carcinoma

United States
Andreana Holowatyj, PhD, MSCI

Recruiting

Genetics of Appendix Cancer Study (GAP)

Appendix Cancer | Appendiceal Neoplasms | Appendix Adenocarcinoma | Appendiceal Cancer | Appendiceal Adenocarcinoma | Appendix Tumor | Appendiceal Mucinous Neoplasm | Appendiceal Carcinoid Tumor | Appendiceal Neoplasm Malignant Secondary | Appendix Mucinous Neoplasm | Appendix Cancer Metastatic | Appendix NET | Low-Grade Appendix Mucinous Neoplasm and other conditions

United States
Sahlgrenska University Hospital, Sweden

Unknown

Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy

Pancreatic Cyst | Pancreatic Neuroendocrine Carcinoma | Pancreatic Pseudocyst | Pancreatic Serous Cystadenoma | Pancreatic Mucinous Cystadenoma | Pancreatic Cystadenocarcinoma | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Solid Pseudopapillary Tumor of the Pancreas
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial Serous Adenocarcinoma | Uterine Corpus Carcinosarcoma

United States, Puerto Rico
Montefiore Medical Center

Completed

A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma

Uterine Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage I Colon Cancer | Stage I Rectal Cancer
Turku University Hospital
University of Helsinki

Recruiting

Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC (DECIDER)

High Grade Serous Carcinoma | High Grade Ovarian Serous Adenocarcinoma

Finland
University of Pennsylvania
AstraZeneca; Myriad Genetics, Inc.

Recruiting

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI)

High Grade Serous Carcinoma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma

United States
M.D. Anderson Cancer Center

Completed

Papillary Serous Carcinoma of the Endometrium

Endometrial Cancer

United States
John Hays
Sanofi

Unknown

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage IV Colon Cancer | Stage IV Rectal Cancer

United States
National Cancer Institute (NCI)

Completed

Edrecolomab in Treating Patients With Stage II Colon Cancer

Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage IIA Colon Cancer | Stage IIB Colon Cancer | Stage IIC Colon Cancer

United States
M.D. Anderson Cancer Center

Terminated

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

Uterine Cancer

United States

Clinical Trials on Cystadenocarcinoma, Mucinous

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations